The researchers systematically searched PubMed, Embase, and the Cochrane Library for studies comparing ADCs with conventional chemotherapy in TNBC. Their final dataset comprised six articles: five randomized controlled trials dedicated to TNBC, plus one exploratory analysis of the hormone receptor–negative, HER2-low subgroup from the DESTINY-Breast04 trial. Together, the studies enrolled 2,479 patients, of whom 1,256 received an ADC and 1,223 received conventional chemotherapy.

The survival results were substantial. The pooled hazard ratio for progression-free survival was 0.48 (95% confidence interval 0.38 to 0.61, P = 0.001), meaning patients treated with ADCs experienced roughly half the risk of disease progression or death at any given time compared with those on chemotherapy. For overall survival, the hazard ratio was 0.60 (95% confidence interval 0.46 to 0.79, P = 0.027), a statistically significant reduction in the risk of death favoring the ADC arm.

Safety outcomes formed an equally important part of the analysis. The odds ratio for the incidence of all adverse events was 1.05 (95% confidence interval 0.86 to 1.29, P = 0.901), and for grade 3 or higher adverse events it was 1.11 (95% confidence interval 0.88 to 1.42, P = 0.984). Neither difference reached statistical significance, indicating that the survival gains achieved by ADCs were not accompanied by a detectable increase in overall toxicity or in severe, treatment-limiting side effects relative to the chemotherapy control arms.

The authors note that the pooled results demonstrated that ADCs significantly improved overall survival and progression-free survival while showing no significant increase in overall adverse events or grade 3 or higher adverse events compared with the control treatment. Because the evidence base combined dedicated TNBC randomized trials with an exploratory subgroup analysis, the two components differ in design and scope, and the DESTINY-Breast04 subgroup result should be weighed accordingly.

The authors state that the findings may inform future head-to-head trials comparing individual ADCs, the optimization of ADC-based combination regimens, and biomarker-guided precision treatment. They also note that as clinical data on novel ADCs continue to accumulate, the conclusions may be further validated and extended.

The study’s stated purpose was to compare the efficacy and safety of ADCs versus conventional chemotherapy in patients with TNBC and to provide evidence for clinical decision-making and guideline development. Within that scope, the meta-analysis quantified both benefit and toxicity using hazard ratios for survival outcomes and odds ratios for safety endpoints, alongside the objective response rate as an efficacy measure.

For clinicians and guideline developers, the analysis offers a pooled estimate of the survival benefit and safety profile of ADCs in TNBC drawn from the randomized evidence currently available. The authors position the work as a foundation that may be refined as additional clinical data on novel ADCs emerge, with biomarker-guided approaches and combination regimens identified as directions for future study.

Subject of Research: Efficacy and safety of antibody-drug conjugates versus conventional chemotherapy in triple-negative breast cancer

Article Title: Antibody-drug conjugates therapy for triple-negative breast cancer: a systematic review and meta-analysis

Article References: Wan, K., & Liu, M. (2026). Antibody-drug conjugates therapy for triple-negative breast cancer: a systematic review and meta-analysis. Frontiers in Medicine, 13, Article 1975216. https://doi.org/10.3389/fmed.2026.1975216

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1975216

Keywords: antibody-drug conjugates, triple-negative breast cancer, meta-analysis, systematic review, chemotherapy, progression-free survival, overall survival, adverse events, DESTINY-Breast04, randomized controlled trials, precision medicine, Antibody-drug